---
title: "Zhejiang AngLiKang Pharmaceutical Subsidiary Receives Approval for Finasteride API"
date: "2025-02-14 14:52:44"
summary: "Zhejiang AngLiKang Pharmaceutical said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse. Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11,..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Zhejiang AngLiKang Pharmaceutical said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.

Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11,Â 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250214:G2467884:0/)
